- Reference code :
- wf407
- Published date :
-
11 December 2001
- Expired date :
-
28 April 2029
AstraZeneca today announced that new data presented at the San Antonio Breast Cancer Meeting demonstrate for the first time that leading aromatase inhibitor Arimidex ® is significantly more effective and has important tolerability benefits compared with the current gold standard, tamoxifen, as an adjuvant treatment in postmenopausal women with early breast cancer.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
